贝达药业(300558.SZ)以5000万元投资知兴制药其专注于高端吸入制剂开发

智通财经01-09

智通财经APP讯，贝达药业(300558.SZ)公告，公司已与花园集团有限公司(简称“花园集团”)完成股权转让交割，公司出资5000万元受让花园集团持有的杭州知兴制药有限公司(简称“知兴制药”)注册资本200万元，投后总占比为20%。公司称，知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。据悉，吸入制剂是指利用吸入装置将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602626329?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-09 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602626329","market":"hk","top_or_hot":-1,"title":"贝达药业(300558.SZ)以5000万元投资知兴制药 其专注于高端吸入制剂开发","media":"智通财经","content":"<div>\n<p>智通财经APP讯，贝达药业(300558.SZ)公告，公司已与花园集团有限公司(简称“花园集团”)完成股权转让交割，公司出资5000万元受让花园集团持有的杭州知兴制药有限公司(简称“知兴制药”)注册资本200万元，投后总占比为20%。公司称，知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。据悉，吸入制剂是指利用吸入装置将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390971.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贝达药业(300558.SZ)以5000万元投资知兴制药 其专注于高端吸入制剂开发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贝达药业(300558.SZ)以5000万元投资知兴制药 其专注于高端吸入制剂开发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1390971.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，贝达药业(300558.SZ)公告，公司已与花园集团有限公司(简称“花园集团”)完成股权转让交割，公司出资5000万元受让花园集团持有的杭州知兴制药有限公司(简称“知兴制药”)注册资本200万元，投后总占比为20%。公司称，知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。据悉，吸入制剂是指利用吸入装置将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1390971.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300558","symbol_name":"贝达药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1390971.html","article_id":"2602626329","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602626329","pubTimestamp":1767950793,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，贝达药业 公告，公司已与花园集团有限公司完成股权转让交割，公司出资5000万元受让花园集团持有的杭州知兴制药有限公司注册资本200万元，投后总占比为20%。公司称，知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。公司本次投资知兴制药，布局高端吸入制剂领域，符合公司长期发展战略，双方围绕创新研发、技术平台等领域开展深度合作。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300558":"贝达药业","BK1574":"生物医药B类股","01477":"欧康维视生物-B","BK0060":"抗癌","BK0239":"医药制造","BK1191":"制药"},"translate_title":"Betta Pharmaceuticals (300558. SZ) invested 50 million yuan in Zhixing Pharmaceutical, which focuses on the development of high-end inhalation preparations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300558":1.5,"01477":1.5},"content_text":"智通财经APP讯，贝达药业(300558.SZ)公告，公司已与花园集团有限公司(简称“花园集团”)完成股权转让交割，公司出资5000万元受让花园集团持有的杭州知兴制药有限公司(简称“知兴制药”)注册资本200万元，投后总占比为20%。公司称，知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。据悉，吸入制剂是指利用吸入装置将药物递送进入呼吸道发挥局部或全身治疗作用的制剂，是一种高技术壁垒的药械合一产品，主要针对呼吸道疾病及其他潜在应用领域的临床治疗。吸入制剂具有给药方便、起效快以及避免肝脏首过效应等优势，被国内外相关指南推荐为哮喘及慢性阻塞性肺疾病(COPD)的优选治疗方法，目前已逐步拓展至疫苗、中枢神经等领域;凭借器官靶向精准性与给药灵活性，吸入制剂亦将为肺癌等肿瘤治疗领域提供了新的探索与应用方向。公司本次投资知兴制药，布局高端吸入制剂领域，符合公司长期发展战略，双方围绕创新研发、技术平台等领域开展深度合作。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602626329","isCrawlerRequest":true}

贝达药业(300558.SZ)以5000万元投资知兴制药 其专注于高端吸入制剂开发

精彩评论

贝达药业(300558.SZ)以5000万元投资知兴制药其专注于高端吸入制剂开发